Joan Llabre, Ph.D. '23, who received her doctorate in biomedical engineering from Rensselaer Polytechnic Institute this past fall and is now a postdoctoral researcher at the Institute, has won the Koerner Family Foundation Fellowship, which supports engineers pursuing careers in research.
Using artificial intelligence tools to analyze years of biomedical data, researchers at Rensselaer Polytechnic Institute have discovered a possible connection between sleep, gastrointestinal health, and two potentially harmful behaviors often associated with profound autism: self-injury and aggression. Their study is published in the Journal of Personalized Medicine.
This spring, a team of biomedical engineering students at Rensselaer Polytechnic Institute helped create a critical component that may be used to diagnose skin cancer rapidly and at the point of care, pending FDA clearance.
Rensselaer Polytechnic Institute has established the Office of Strategic Alliances and Translation, a new area within the university that incorporates a number of key translational activities at RPI, including intellectual property and technology licensing, large-scale corporate partnerships, initiation and growth of start-up ventures, and translational campuses, including the Rensselaer Technology Park, as well as translational activities in New York City.
This past summer, a team of Rensselaer Polytechnic Institute students, with the guidance of a faculty mentor, pitched a winning design for a wearable, medical-grade device that monitors for atrial fibrillation. Atrial fibrillation, or A-fib, is a potentially life-threatening heart condition that will affect an estimated 12 million people in the U.S. by 2030, according to the Centers for Disease Control and Prevention.
RPI and Albany Medical College Researchers Awarded $3.3 Million To Improve Breast Cancer Treatment Using Artificial Intelligence
Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College were awarded a $3.3 million grant over five years by the National Cancer Institute to use artificial intelligence (AI) to improve targeted drug therapy in HER2-positive breast cancer treatment. HER2-positive breast cancer tends to grow and spread quickly, but targeted treatments improve outcomes.